The study's objectives were to grade the patients based on their sputum smear grading and estimate the predictive value of Tuberculosis using serum adenosine deaminse (ADA). The present study was a hospital‐based cross‐sectional study on 40 patients who tested positive on sputum smear microscopy. The positive samples are graded into 1+, 2+ and 3+ on microscopy based on the severity. Serum ADA was sent for each patient and their values were correlated with the Sputum microscopy grading. The Majority (80%) of subjects in the present study were male. The most common symptom with which the subjects presented was cough. This was followed by shortness of breath, fever, weight loss and hemoptysis. Smoking was noted in the Majority (70%) of the study subjects. The Majority (85%) of the subjects were newly diagnosed cases of pulmonary Tuberculosis. The remaining were reinfection cases. The most common sputum smear grading was Grade‐1 (40%), followed by Grade‐2 (35%) and Grade‐3 (25%). Serum ADA Levels were highest in Grade‐3 subjects, followed by Grade‐2 and Grade‐1. This difference was found to be statistically significant. The diagnostic utility of serum ADA for diagnosis of Grade‐1 smear‐positive tuberculosis was not found to be adequate (AUC=0.19). The diagnostic utility of serum ADA for diagnosis of Grade‐2 smear‐positive tuberculosis was not found to be adequate (AUC=0.49). The diagnostic utility of serum ADA for diagnosing Grade‐3 smear‐positive tuberculosis was good (AUC=0.89). As the AUC is highest for 3+grading patients, this is significant only in 3+pulmonary Tuberculosis. This indicates that the bacterial load is important for the raised ADA levels. Finally indicates that serum ADA may be useful in Multi bacillary Tuberculosis rather than Pauci bacillary Pulmonary Tuberculosis.
P.N. Kiran Kumar and C. Ramanjula Reddy. Study on Levels of Serum Adenosine Deaminse Levels in Patients with Pulmonary Tuberculosis.
DOI: https://doi.org/10.36478/10.36478/makrjms.2022.4.99.102
URL: https://www.makhillpublications.co/view-article/1815-9346/10.36478/makrjms.2022.4.99.102